Abstract library

61 results for "Europe".
#2209 The ENETS Registry: First Results of a Collaborative Effort Including over 12.000 Patients with Neuroendocrine Neoplasms (NENs) from 7 European Countries
Introduction: NENs are rare and global European epidemiologic data are only based on national or compilation of national registries. So, there is a need for comprehensive homogenous information
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Dr. Ivan Borbath
#2035 Prevalence of Carcinoid Syndrome (CS) in the European Union (EU)
Introduction: Epidemiologic data on CS, which typically occurs in patients with advanced midgut or lung neuroendocrine tumors (NET), are scarce and appear to be heterogeneous across countries.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MSc Julie Mouchet
#427 Gastric Carcinoids: Prevalence in Europe and USA, and Rationale for Treatment with YF476, a Gastrin Receptor Antagonist
Introduction: Gastric carcinoids (GC) are tumors arising from enterochromaffin-like (ECL) cells in the gastric mucosa. Most are caused by hypergastrinaemia, which stimulates ECL-cell growth. YF476 is a potent, selective and orally active gastrin receptor antagonist in humans in vitro and in vivo. YF476 prevented and caused shrinkage of GC in animal models of the condition.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Malcolm Boyce
Authors: Boyce M, ...
#1480 Systemic Treatment Sequences across Europe for Patients (pts) with Advanced Non-functional (NF) Well-Differentiated Pancreatic Neuroendocrine Tumours (WD pNETs)
Introduction: Different systemic therapies (ST) are available for pts with advanced WD pNETs; however, the best treatment modalities and optimal sequencing are currently unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MD PhD Ana Custodio
#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Maximilian Heetfeld
#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Côme Lepage
#1799 Pilot Electronic Survey to Locate Nurses Caring for NET Patients in Europe.
Introduction: There is an assumed variance in the roles nurses have in looking after NET patients, and the different levels of knowledge.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Philippa Davies
#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Marianne E Pavel
#956 Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors
Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ingrid Holst Olsen
#1092 Experience of Two European Centers on Central Pancreatectomy for NeuroEndocrine Tumors of the Pancreas
Introduction: Central pancreatectomy (CP) is a parenchima-sparing operation that enables the removal of benign or low-grade malignant lesions from the neck of the pancreas.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Doctor Valbona Lico